March 11, 2022
PAR-20-084 - NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)
National Institute on Aging (NIA)
This Notice informs potential applicants that the National Institute on Aging (NIA) is participating, effective immediately, in Funding Opportunity Announcement (FOA) PAR-20-084, "NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)."
The following sections of PAR-20-084 have been modified:
Part 1. Overview Information
Components of Participating Organizations
Currently Reads:
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Modified to Read (changes shown in bold italics):
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
National Institute on Aging (NIA)
Catalog of Federal Domestic Assistance (CFDA) Number(s)
Currently Reads:
93.286
Modified to Read (changes shown in bold italics):
93.286, 93.866
Part 2. Full Text of Announcement
Section I. Funding Opportunity Description
This section was modified to add:
National Institute on Aging (NIA)
NIA leads the federal government in conducting and supporting research on aging and the health and well-being of older people. To fulfill its mission, NIA supports technologies which aim to increase the research community's understanding of the aging process, as well as diseases, conditions, and needs associated with growing older, in order to extend the healthy, active years of life. Studies of interest to NIA include, but are not limited to, the following:
Section VII. Agency Contacts
This section was modified to add:
Scientific/Research Contact(s)
Leonid Tsap, Ph.D.
Division of Aging Biology (DAB)
National Institute on Aging (NIA)
Phone: 301-594-0277
Email: [email protected]
Financial/Grants Management Contact(s)
Jessi Perez
National Institute on Aging (NIA)
Phone: 301-496-1472
Email: [email protected]
All other aspects of the FOA remain the same.
Leonid Tsap, Ph.D.
Division of Aging Biology (DAB)
National Institute on Aging (NIA)
Phone: 301-594-0277
Email: [email protected]